Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Company decision to terminate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This registry is intended to measure the effect of myPlan Lung Cancer™ test has on treatment decisions of Surgeons when added to standard clinical-pathological parameters in patients with early stage NSCLC.The sponsor is conducting two parallel registries, with one directed at Surgeons (ONC003) and the other at Oncologists (ONC006).This registry is specific to Surgeons (ONC003). Outcomes measures on lung cancer relapse and death from any cause will be collected.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Percentage change from Pre-Test to Post-Test referral | The percentage change from the recorded PRE-TEST referral by surgeon versus the POST-TEST referral following results of myPlan Lung Cancer testing | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage change from the Pre-test referral to the 60-day Post-Test referral | The percentage change from the recorded Pre-Test referral by surgeon versus the 60 day post-test actual referral attendance | 2 months |
| Percentage of patients at 60 days post test receiving treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Recently diagnosed treatment-naïve patients with early stage NSCLC (lung adenocarcinoma)
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Richard Wenstrup, MD | Myriad Genetic Laboratories, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seattle | Washington | United States |
Not provided
Not provided
Not provided
Not provided
Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic adenocarcinoma biopsies.
The percentage of patients at 60 day post-test who are receiving radiation and or chemotherapy treatment |
| 2 months |
| Percentage change from Pre-Test to Post-Test chest surveillance plan | The percentage change from the recorded Pre-Test chest surveillance plan versus the Post-Test chest surveillance plan | 3 months |
| Assessment of disease free survival from resection to relapse or death | Disease-free survival, which is defined as the time from resection to the first of two events: lung cancer relapse or death from any cause | 3 years |
| ID | Term |
|---|---|
| D008175 | Lung Neoplasms |
| D000077192 | Adenocarcinoma of Lung |
| ID | Term |
|---|---|
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided